Kestra Stops Selling a Gross-Margin Story and Starts Selling Rep Productivity

Revenue +60%, an 11th straight quarter of margin expansion, a raised FY27 guide — and a brand-new theme sitting at the very top of the company's keyword ranking.

KMTS · Earnings Call · 2026-09-14

The Beat Is Only Half the Story

Kestra Medical Technologies reported fiscal Q1 2027 on September 14 and the headline numbers were clean across the board: revenue of $31M, up 60% year over year, gross margin of 56.5% versus 45.7% a year ago, and a fiscal-2027 revenue guide raised to $141M — 48% growth — from $137M. On the surface this is the same story Kestra has told since its IPO: a fast-growing wearable cardioverter defibrillator franchise compounding off a small base. But two things changed this quarter that make it worth a closer look. First, management lifted its long-term gross-margin target to the mid-70s from 70%. “We have now expanded gross margins 11 quarters in a row with margin increasing over 10 points year-over-year... We have good line of sight to achieving gross margins of the mid-70%...” The mechanics are unglamorous but durable: higher in-network mix (up from roughly 70% at IPO to the low 80s), a falling cost per fit, and supplier volume leverage. Gross margin has climbed from about 33% to the mid-50s over the past year, and the trajectory has been almost stubbornly linear. A year ago the aspiration was "70% plus" — the goalpost moved this quarter. Second — and more interesting — the company's narrative center of gravity moved.

From Conversion Rate to Rep Productivity

For several quarters Kestra's keyword mix was dominated by conversion rate, network mix, and the clinical specialist. This quarter those concepts slipped, and a fresh theme vaulted to the top of the company's own ranking: rep productivity, paired with path to profitability. That is a tell. Management is now explicitly selling an operating-leverage story, not merely a top-line one.

...when we think about the path to profitability, that path to profitability, that road runs right through rep productivity. And that's why we're investing in some of those tools...

The lever is AI tools layered onto a technology stack the company has quietly been building. Brian Webster framed three priorities — patient support and adherence, revenue-access and collections automation, and commercial demand acceleration — the last measured by "patient fittings per rep without requiring a proportional increase in headcount." The finance chief was equally blunt that the payoff is back-loaded: “We've started to see that gradually here in FY '27. We expect that to accelerate in FY '28 and '29 as we implement more of the technologies.” This is a genuine shift in emphasis from prior calls. In July the conversation was about firing up sales capacity and the limits of endlessly adding territories. “I do not think that our model requires us to continually add new reps. We have lots of opportunity to gain market share and to grow the productivity levels on a territory level.” Now that same efficiency argument has been elevated into the primary path to profits.

An AI Theme That Is Not Kestra's Alone

Here is where the company's story collides with the broader market. The global theme tape over the last 30 days is led by AI at scale, while this week's reporters are racing to staple AI onto their franchises — Adobe with agentic software, Oracle with "agentic studios" and an AI Data Platform. Kestra is riding that wave, not creating it. The twist is that its AI case is unusually concrete: each initiative is mapped to a named KPI — fittings per rep, collections conversion, G&A cost per dollar of revenue — rather than to product buzzwords. Whether that discipline holds as the spending ramps is the thing to watch. The near-term bill is real. Research and development rose about 70% year over year to finish a late-stage program, pushing GAAP operating expense to $55.2M and GAAP operating income to roughly -$39M. Management insists the R&D run-rate returns to the 5–7% range in the second half, which is what makes the leverage math credible rather than aspirational.

Market Access, and the Themes That Quietly Fell Away

Beneath the AI narrative, the most underappreciated line was market access. A "significant national payer" expanded coverage to non-ischemic patients — the first time that large payer has covered both populations, and notable since more than 60% of a typical WCD population is non-ischemic. “Among the large payers, I would say this was the outlier. Most of the large payers already covered that patient population.” That converts a laggard payer into evidence that clinical data is now moving coverage policy — a slow-burn catalyst for the WCD market expansion that management pegs at roughly 14% on a dollar basis. What faded matters too. The new algorithm update, once a marquee topic, declined in the keyword ranking — it is now fully deployed and no longer news. Clinical specialist and revenue-cycle-management capability similarly cooled. The interesting contrast: the company's old proof points are graduating from "initiative" to "installed base," and the fresh proof points are efficiency and profitability. The stock gives the report a mixed reception. Capital expenditure is running at roughly $10M a quarter and the tape shows KMTS up 22.5% over the last 90 days but 11.2% off its August 10 peak — a name in motion that has already priced in a lot of good news. The bottom line: Kestra did not change its product story this quarter; it changed its financial one. The mid-70s margin target and the rep-productivity framing are an attempt to turn a growth stock into a growth-plus-leverage story. That is a promise in FY27 and a delivery in FY28–29. The market, up sharply into the print, will grade it on whether the cost curve actually bends.